We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FABHALTA (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
FABHALTA
Date registered
Evaluation commenced
Decision date
Approval time
212 (255 working days)
Active ingredients
iptacopan
Registration type
NCE/NBE
Indication
FABHALTA is indicated for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.